drugset / Trial / NCT07364370

Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery

NCT07364370

Not yet recruiting 50 enrolled Cairo University
RandomizedParallel-groupTriple-blindPrevention

Summary

Myopic shift remains a debilitating and unpredictable adverse event following pediatric cataract surgery. While research exploring peripheral myopic defocus for post-cataract surgery myopia prevention shows promising results, the use of multifocal intra-ocular lenses (IOLs) cannot be used liberally in countries with high disease burden and challenged economies due to high price and decreased availability. To date there are no studies evaluating the use of topical atropine for the management of myopic shift following pediatric cataract surgery. The investigators aim to explore the use of 0.05% topical atropine in the prevention and management of myopic shift following pediatric cataract surgery.

Timeline

Start
2026-02
Primary completion
2027-08
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.05 % Topical